Potential Deleterious Effects of Vasopressin in Chronic Kidney Disease and Particularly Autosomal Dominant Polycystic Kidney Disease

被引:28
|
作者
Meijer, E. [1 ]
Boertien, W. E. [1 ]
Zietse, R. [2 ]
Gansevoort, R. T. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands
[2] Erasmus MC, Dept Nephrol, Rotterdam, Netherlands
关键词
Vasopressin; Copeptin; Chronic kidney disease; Autosomal dominant polycystic kidney disease; Albuminuria; Proteinuria; Glomerular filtration rate; RENAL CONCENTRATING CAPACITY; GLOMERULAR-FILTRATION-RATE; RENIN-ANGIOTENSIN SYSTEM; RECEPTOR ANTAGONISTS; DIABETES-MELLITUS; ANTIDIURETIC ACTION; PLASMA VASOPRESSIN; SURROGATE MARKER; BRATTLEBORO RATS; SODIUM-EXCRETION;
D O I
10.1159/000326902
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The antidiuretic hormone vasopressin is crucial for regulating free water clearance in normal physiology. However, it has also been hypothesized that vasopressin has deleterious effects on the kidney. Vasopressin is elevated in animals and patients with chronic kidney disease. Suppression of vasopressin activity reduces proteinuria, renal hypertrophy, glomerulosclerosis and tubulointerstitial fibrosis in animal models. The potential detrimental influence of vasopressin is probably mediated by its effects on mesangial cell proliferation, renin secretion, renal hemodynamics, and blood pressure. In this review, we discuss the increasing body of evidence pointing towards the contribution of vasopressin to chronic kidney disease progression in general and to autosomal dominant polycystic kidney disease in particular. These data allude to the possibility that interventions directed at lowering vasopressin activity, for example by the administration of vasopressin receptor antagonists or by drinking more water, may be beneficial in chronic kidney disease. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码:235 / 244
页数:10
相关论文
共 50 条
  • [1] Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease: Reliable Indicators of Vasopressin Activity and Disease Prognosis?
    Casteleijn, Niek F.
    Zittema, Debbie
    Bakker, Stephan J. L.
    Boertien, Wendy E.
    Gaillard, Carlo A.
    Meijer, Esther
    Spithoven, Edwin M.
    Struck, Joachim
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF NEPHROLOGY, 2015, 41 (03) : 248 - 256
  • [2] Copeptin, a Surrogate Marker of Vasopressin, Is Associated with Disease Severity in Autosomal Dominant Polycystic Kidney Disease
    Meijer, Esther
    Bakker, Stephan J. L.
    van der Jagt, Eric J.
    Navis, Gerjan
    de Jong, Paul E.
    Struck, Joachim
    Gansevoort, Ron T.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (02): : 361 - 368
  • [3] Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease
    Devuyst, Olivier
    Torres, Vicente E.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (04) : 459 - 470
  • [4] Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease
    Horie, Shigeo
    Muto, Satoru
    Kawano, Haruna
    Okada, Tadashi
    Shibasaki, Yoshiyuki
    Nakajima, Koji
    Ibuki, Tatsuki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (05) : 467 - 478
  • [5] Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?
    Higashihara, Eiji
    Nutahara, Kikuo
    Tanbo, Mitsuhiro
    Hara, Hidehiko
    Miyazaki, Isao
    Kobayashi, Kuninori
    Nitatori, Toshiaki
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (09) : 1710 - 1719
  • [6] Kidney volume and function in autosomal dominant polycystic kidney disease
    Higashihara, Eiji
    Nutahara, Kikuo
    Okegawa, Takatsugu
    Shishido, Toshihide
    Tanbo, Mitsuhiro
    Kobayasi, Kuninori
    Nitadori, Toshiaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (01) : 157 - 165
  • [7] Kidney volume and function in autosomal dominant polycystic kidney disease
    Eiji Higashihara
    Kikuo Nutahara
    Takatsugu Okegawa
    Toshihide Shishido
    Mitsuhiro Tanbo
    Kuninori Kobayasi
    Toshiaki Nitadori
    Clinical and Experimental Nephrology, 2014, 18 : 157 - 165
  • [8] Renal disease progression in autosomal dominant polycystic kidney disease
    Higashihara, Eiji
    Horie, Shigeo
    Muto, Satoru
    Mochizuki, Toshio
    Nishio, Saori
    Nutahara, Kikuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2012, 16 (04) : 622 - 628
  • [9] Renal disease progression in autosomal dominant polycystic kidney disease
    Eiji Higashihara
    Shigeo Horie
    Satoru Muto
    Toshio Mochizuki
    Saori Nishio
    Kikuo Nutahara
    Clinical and Experimental Nephrology, 2012, 16 : 622 - 628
  • [10] Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease
    Fassett, Robert G.
    Coombes, Jeff S.
    Packham, David
    Fairley, Kenneth F.
    Kincaid-Smith, Priscilla
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2010, 44 (01): : 56 - 61